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Objectives This study sought to determine the incidence of aspirin nonresponsiveness in addition to clopidogrel nonresponsive-
ness and whether this association identifies patients at an increased risk of drug-eluting stent (DES) thrombosis.
Background Nonresponsiveness to clopidogrel is a predictor of DES thrombosis. No prospective data exist about the possible
association of dual nonresponsiveness to clopidogrel and aspirin with DES thrombosis.
Methods Platelet function was assessed after a loading dose of 600 mg clopidogrel in 746 patients who had successful
DES implantation followed by 6-month dual-antiplatelet therapy. Platelet reactivity was assessed by light trans-
mittance aggregometry using adenosine 5=-diphosphate, arachidonic acid, and collagen. The primary end point
was definite/probable DES thrombosis at 6 months. The secondary end point was the composite of cardiac
mortality and DES thrombosis.
Results The incidence of dual nonresponsiveness to aspirin and clopidogrel was 6%. Definite/probable DES thrombosis
was significantly higher in dual aspirin and clopidogrel nonresponders (11.1%) than in clopidogrel and aspirin
responders (2.1%, p  0.001), isolated clopidogrel nonresponders (2.2%, p  0.05), or aspirin nonresponders
(2.3%, p  0.05). The incidence of the secondary end point was 4.4% in isolated clopidogrel nonresponders,
2.3% in isolated aspirin nonresponders, and 13.3% in dual aspirin and clopidogrel nonresponders. Dual clopi-
dogrel and aspirin nonresponsiveness was an independent predictor of DES thrombosis (hazard ratio: 3.18, 95%
confidence interval: 1.14 to 8.83, p  0.027) and the composite of cardiac mortality and DES thrombosis
(hazard ratio: 2.94, 95% confidence interval: 1.16 to 7.41, p  0.022).
Conclusions Dual nonresponsiveness to aspirin and clopidogrel is a relatively infrequent condition that identifies patients at a
very high risk of DES thrombosis or death. (J Am Coll Cardiol 2008;52:734–9) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.032a
R
E
s
d
p
n
e
R
i
d
fiual antiplatelet treatment with clopidogrel and aspirin is
he standard treatment in patients treated with drug-eluting
tents (DES) for coronary artery disease for the prevention
f DES thrombosis (1–3). Early discontinuation of dual
ntiplatelet treatment is a strong predictor of DES throm-
osis (4–7). However, DES thrombosis can occur also in
atients who are compliant with dual antiplatelet treatment,
nd several retrospective studies and 2 prospective studies
ave shown that high residual platelet reactivity during
ntiplatelet treatment is related to the risk of thrombosis
rom the *Department of Medical and Surgical Critical Care, University of Florence,
lorence, Italy; †Department of Cardiology, Careggi Hospital, Florence, Italy; and
he ‡Center Santa Maria agli Ulivi, Don Carlo Gnocchi Foundation, Istituto di
icovero e Cura a Carattere Scientifico, Impruneta, Florence, Italy.w
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ccepted May 6, 2008.nd other adverse events (8–14). The RECLOSE (Low
esponsiveness to Clopidogrel and Sirolimus- or Paclitaxel-
See page 740
luting Stent Thrombosis) trial has shown that nonrespon-
iveness to a loading dose of 600 mg clopidogrel is indepen-
ently related to the risk of DES thrombosis (14). No
rospective data exist about the possible association of dual
onresponsiveness to clopidogrel and aspirin with thrombotic
vents in patients with DES. This study, based on the
ECLOSE trial patient cohort, sought to determine the
ncidence of aspirin nonresponsiveness in addition to clopi-
ogrel nonresponsiveness and whether this association identi-
es patients at increased risk of DES thrombosis compared
ith isolated nonresponsiveness to clopidogrel.
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atients. The RECLOSE trial is a prospective study that
ncluded 804 consecutive patients who were treated with
irolimus-eluting (Cypher, Cordis Corporation, Miami
akes, Florida) or paclitaxel-eluting (Taxus, Boston Scien-
ific Corporation, Natick, Massachusetts) stents for coro-
ary artery disease and who were compliant with 6-month
ual antiplatelet treatment with aspirin (325 mg daily) and
lopidogrel (75 mg daily). Patients with stable coronary
rtery disease as well as acute coronary syndromes and
T-segment elevation acute myocardial infarction were
ncluded irrespective of the coronary anatomy. The only
xclusion criteria were: 1) in-hospital death not caused by
ES thrombosis; 2) anticipated noncompliance with dual
ntiplatelet treatment for at least 6 months; and 3) prema-
ure discontinuation of clopidogrel or aspirin therapy. The
tudy showed that nonresponsiveness to clopidogrel was
ssociated with a 3-fold increase in DES thrombosis (haz-
rd ratio [HR]:  3.08, 95% confidence interval [CI]: 1.32
o 7.16, p  0.009) compared with responsiveness. Details
f the study have been published elsewhere (14).
latelet reactivity assessment. By light transmittance ag-
regometry, we evaluated platelet reactivity testing respon-
iveness to clopidogrel with adenosine 5=-diphosphate
ADP) and to aspirin with arachidonic acid. Furthermore,
e evaluated platelet reactivity using collagen that is an
ggregation stimulus not directly involved in the specific
athways of clopidogrel and aspirin. Blood samples antico-
gulated with 0.129 mol/l sodium citrate (ratio 9:1) were
btained 12 to 18 h after 600-mg clopidogrel loading. For
atients receiving both the loading dose of clopidogrel and
glycoprotein (GP) IIb/IIIa inhibitor in the catheterization
aboratory, blood samples were obtained after 6 days, while
atients were on the 75-mg maintenance dose of clopidogrel
nd 325 mg aspirin. Platelet-rich plasma, obtained by
entrifuging whole blood for 10 min at 200 g, was stimu-
ated with 10-M ADP, 1-mM arachidonic acid, and
-g/ml collagen, and residual aggregation was assessed
sing a light transmittance aggregometer (APACT4, Helena
aboratories, Milan, Italy). The 100% line was set using
latelet-poor plasma, and the 0 baseline was established with
latelet-rich plasma (adjusted from 18  109/l up to 30 
09/l). Platelet aggregation (according to the Born method)
as evaluated considering the maximal percentage of platelet
ggregation in response to stimulus. The coefficient of variation
f ADP–, arachidonic acid–, and collagen–platelet aggregation
ere 6.8%, 5.8%, and 5.6%, respectively. Clopidogrel nonre-
ponsiveness was defined as platelet aggregation by ADP
70% (14), and aspirin nonresponsiveness as platelet aggrega-
ion by arachidonic acid 20% (15). High residual platelet
eactivity by collagen was defined as platelet aggregation above
he 90th percentile of aggregation value distribution that
esulted in 56%.
nd points. The primary end point of the study was
efinite or probable DES thrombosis during 6-month collow-up. Definite stent throm-
osis was defined as acute coro-
ary syndrome and either angio-
raphic or pathological confir-
ation of thrombosis. Probable
tent thrombosis was defined as
udden or otherwise explained
eath or nonfatal myocardial in-
arction in the territory supplied
y a stented vessel without an-
iographic confirmation. The diagnosis of myocardial in-
arction was based on either the development of new Q
aves on 2 or more electrocardiographic leads or an increase
f creatine kinase-myocardial band isoenzyme or troponin T
3 the upper limit of normal. Event time was categorized
s acute (within 24 h from stent implantation), subacute
from 1 to 30 days), and late (30 days to 6 months). The
econdary end point was the composite of cardiac mortality
nd definite or probable stent thrombosis. All events were
djudicated by 3 observers (A.M., D.A., G.M.) who were
linded to patient responsiveness to clopidogrel and aspirin
nd were not involved in the follow-up process.
ollow-up. All patients had scheduled clinical and electro-
ardiographic examinations at 1, 3, and 6 months. All other
ossible information derived from hospital readmission or
y the referring physician, relatives, or municipality live
egistries was entered into the database.
tatistical analysis. Discrete data are summarized as fre-
uencies, whereas continuous data are summarized as mean
D. The chi-square test was used for comparison of categorical
ariables, and the 2-tailed Student t test was used to test
ifferences among continuous variables.
Platelet reactivity test correlations were tested using the
-tailed Spearman correlation coefficient entering responses
o ADP, arachidonic acid, and collagen as continuous
ariables. The chi-square test was used for comparison
mong the 4 patient groups, including the post-hoc analysis.
he multivariate analysis to evaluate the independent con-
ribution of clinical, angiographic, procedural, and platelet
eactivity variables to the primary and secondary end points
as performed by a forward stepwise Cox proportional
azards model. Dichotomous platelet reactivity variables
ccording to nonresponsiveness criteria were used (clopi-
ogrel nonresponsiveness, aspirin nonresponsiveness, and
he interaction term dual aspirin and clopidogrel nonre-
ponsiveness). The other variables entered into the model
ere: age (years), male gender, family history of coronary
rtery disease, smoker, hypertension, hypercholesterolemia,
iabetes mellitus, history of myocardial infarction, history of
oronary surgery, acute coronary syndrome, acute ST-
egment elevation myocardial infarction, left ventricular
jection fraction (%), multivessel disease, bifurcation lesion,
hrombus-containing lesion, chronic total occlusion, and
tent length (mm). Survival curves were generated using the
aplan-Meier method, and the difference between the
Abbreviations
and Acronyms
ADP  adenosine
5=-diphosphate
CI  confidence interval
DES  drug-eluting stent(s)
GP  glycoprotein
HR  hazard ratiourves was assessed by a log-rank test. A value of p  0.05
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Dual Nonresponsiveness to Clopidogrel and Aspirin August 26, 2008:734–9as considered significant. Analyses were performed using
he software package SPSS version 8.0 (SPSS Inc., Chicago,
llinois).
esults
f 804 patients enrolled in the study, complete platelet
eactivity data were available for 746 (93%). Clinical and
rocedural characteristics of the patients investigated ac-
ording to platelet reactivity are presented in Table 1.
The incidence of dual nonresponsiveness to aspirin and
lopidogrel was 6%, whereas isolated nonresponsiveness to
Baseline Characteristics
Table 1 Baseline Characteristics
Dual
Responders
(n  570)
Non
(
Age (yrs) 67 12 7
Male gender 435 (76.3) 3
Current smokers 142 (24.9)
Arterial hypertension 351 (61.6) 3
Diabetes mellitus 97 (17.0) 1
Hypercholesterolemia 281 (49.3) 1
Prior MI 135 (23.7) 1
Prior PCI 125 (22.0)
Prior CABG 34 (6.0)
Stable angina 186 (32.6) 1
Unstable angina 206 (36.1) 2
Acute MI† 174 (30.5)
Renal failure 60 (10.5)
Multivessel disease 306 (54.1) 3
LVEF (%) 48 11 4
Multivessel PCI 211 (37.0) 2
Thrombus-containing lesion 140 (24.6)
Bifurcation lesion 202 (35.4) 1
Chronic total occlusion 58 (10.1)
Total stent length (mm) 35.6 26.8 51
Sirolimus-eluting stent 317 (55.6) 2
Paclitaxel-eluting stent 223 (39.1) 1
Both stent types 30 (5.3)
Post-PCI MLD (mm) 2.88 0.45 2.8
GP IIb/IIIa inhibitor 258 (45.3) 1
Data are expressed as n (%) unless otherwise specified. *p  0.01 v
aspirin responders; ‡p  0.001 versus clopidogrel and aspirin respon
CABG coronary artery bypass grafting; GP glycoprotein; LVEF l
lumen diameter; PCI  percutaneous coronary intervention.
6-Month Clinical Outcome
Table 2 6-Month Clinical Outcome
Dual
Responders
(n  570)
Definite/probable stent thrombosis, n (%) 12 (2.1)
Definite 6 (1.1)
Probable 6 (1.1)
Cardiac death, n (%) 9 (1.6)
Composite of cardiac death and stent
thrombosis, n (%)
15 (2.6)*p  0.0001; †p  0.05 dual clopidogrel and aspirin nonresponders versus
aspirin nonresponders versus clopidogrel and aspirin responders.lopidogrel or to aspirin was 6% and 11.5%, respectively.
he responses to the 3 stimuli were all correlated: correla-
ion coefficient of ADP and arachidonic acid  0.536 (p 
.001), of ADP and collagen  0.550 (p  0.001), and of
rachidonic acid and collagen  0.617 (p  0.001). The
ollow-up rate was 100%. Table 2 summarizes the clinical
utcome at 6 months according to responsiveness to aspirin,
lopidogrel, or both drugs.
Overall, definite or probable DES thrombosis occurred in
0 patients (2.7%). Patients with dual nonresponsiveness to
lopidogrel and aspirin had the highest incidence of DES
nders
5)
Isolated Clopidogrel
Nonresponders
(n  45)
Isolated Aspirin
Nonresponders
(n  86)
* 70 11 72 11
) 30 (66.7) 65 (75.6)
)† 7 (15.6) 16 (18.6)
) 29 (64.4) 55 (64.0)
)‡ 13 (28.9)† 23 (26.7)†
) 29 (64.4)† 40 (46.5)
) 15 (33.3) 21 (24.4)
) 14 (31.1) 22 (25.6)
2 (4.4) 5 (5.8)
) 16 (35.6) 34 (39.5)
)‡ 22 (48.9) 43 (50.0)†
)† 6 (13.3)† 8 (9.3)‡
) 6 (13.3) 10 (11.6)
)† 27 (60.0) 57 (66.3)†
5 46 13 46 13
)* 21 (46.7)† 47 (54.7)*
)† 3 (6.7)* 10 (11.6)*
) 19 (42.2) 31 (36.0)
) 6 (13.3) 10 (11.6)
6.2‡ 36.2 25.5 44.1 36.9*
) 23 (51.1) 46 (53.5)
17 (37.8) 30 (34.9)
5 (11.1) 10 (11.6)
.46 2.81 0.43 2.84 0.50
) 18 (40.0) 30 (34.9)
lopidogrel and aspirin responders; †p  0.05 versus clopidogrel and
ricular ejection fraction; MImyocardial infarction; MLDminimum
Dual
Nonresponders
(n  45)
Clopidogrel
Nonresponders
(n  45)
Aspirin
Nonresponders
(n  86)
5 (11.1)* 1 (2.2) 2 (2.3)†
2 (4.4) 0 1 (1.2)
3 (6.7)‡ 1 (2.2) 1 (1.2)
4 (8.9)§ 2 (4.4) 1 (1.2)†
6 (13.3)* 2 (4.4) 2 (2.3)†Dual
respo
n  4
3 9
3 (73.3
5 (11.1
0 (66.7
9 (42.2
9 (42.2
2 (26.7
9 (20.0
4 (8.9)
3 (28.9
7 (60.0
6 (13.3
7 (15.5
3 (73.3
4 1
6 (57.8
5 (11.1
6 (35.6
9 (20.0
.7 3
3 (51.1
8 (40)
4 (8.9)
4 0
6 (35.6
ersus c
ders.aspirin nonresponders; ‡p  0.05; §p  0.001 dual clopidogrel and
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r isolated nonresponsiveness to clopidogrel or aspirin was
ssociated with similar rates of DES thrombosis (2.1%,
.2%, and 2.3%, respectively; p value among 4 groups 
.005). Again, the secondary end point rate in patients with
ual nonresponsiveness to aspirin and clopidogrel was 3- to
-fold higher as compared with the other 3 groups: 13.3% in
ual nonresponders, 2.6% in dual responders, 4.4% in
solated clopidogrel nonresponders, and 2.3% in isolated
spirin responders (p value among 4 groups  0.002).
onsistent with the results of a previous study (14), nonre-
Figure 1 Kaplan-Meier Analysis
Kaplan-Meier analysis of drug-eluting stent thrombosis (A) and the composite
of cardiac death and drug-eluting stent thrombosis (B) for dual responders,
dual nonresponders, isolated aspirin nonresponders, and isolated clopidogrel
nonresponders.ponsiveness to clopidogrel with or without nonresponsive- aess to aspirin (n  90) was associated with an increased
isk of DES thrombosis: in the 90 patients, the incidence of
ES thrombosis was 6.7% (HR: 3.15, 95% CI: 1.21 to
.20, p  0.019). Nonresponsiveness to aspirin and dual
onresponsiveness were related to the primary end point
HR: 2.56, 95% CI: 1.02 to 6.40, p  0.045; and HR: 5.31,
5% CI: 1.93 to 14.60, p  0.001, respectively).
The Kaplan-Meier survival curves (Fig. 1) show that the
verall risk of DES thrombosis and the composite of cardiac
eath and DES thrombosis were higher among dual non-
esponders compared with the other 3 groups (primary end
oint: dual nonresponders vs. dual responders, p  0.001;
ual nonresponders vs. aspirin nonresponders, p  0.036;
ual nonresponders vs. clopidogrel nonresponders, p 
.096; secondary end point: dual nonresponders vs. dual
esponders, p  0.001; dual nonresponders vs. aspirin
onresponders, p  0.011; dual nonresponders vs. clopi-
ogrel nonresponders, p  0.127).
When platelet function was assessed by collagen, which
xplores receptors other than those involved in aspirin and
lopidogrel pathways, more than one-half of dual nonre-
ponder patients showed an abnormal platelet reactivity (24
f 45 dual nonresponders). In this subgroup of patients, the
ncidence of the primary end point was higher than in those
ithout residual platelet reactivity (20.8% and 1.8%, respec-
ively; p  0.001). In the other 3 groups, the incidences of
bnormal collagen test results were 15.6% (7 patients) in the
solated clopidogrel nonresponder group, 32.6% (28 pa-
ients) in the isolated aspirin nonresponder group, and 3.3%
19 patients) in the dual responder group.
At multivariable analysis (Table 3), dual nonresponsive-
ess to clopidogrel and aspirin was an independent predictor
f both DES thrombosis (HR: 3.18, 95% CI: 1.14 to 8.83,
 0.027) and the composite of cardiac mortality and DES
hrombosis (HR: 2.94, 95% CI: 1.16 to 7.41, p  0.022).
he other variables related to the risk of DES thrombosis
nd the composite of cardiac death and DES thrombosis
ere age, total stent length, and left ventricular ejection
raction. If aspirin nonresponsiveness and clopidogrel non-
esponsiveness were forced into the multivariable model, the
Rs for the primary end point were 1.44 (95% CI: 0.54 to
.82, p  0.463) and 2.23 (95% CI: 0.85 to 5.82, p 
.101), respectively.
iscussion
his study shows that a high residual platelet reactivity after
loading dose of 600 mg clopidogrel as revealed by 1 or
ore stimuli is relatively frequent and can be revealed in
early one-fourth of patients treated with coronary DES.
owever, dual nonresponsiveness to aspirin and clopidogrel
nvolves only 6% of patients. Patients with dual nonrespon-
iveness to clopidogrel and aspirin have a very high risk of
ES thrombosis during a 6-month follow-up in compari-
on with dual responders or with isolated clopidogrel or
spirin nonresponders. The present novel findings are not
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Dual Nonresponsiveness to Clopidogrel and Aspirin August 26, 2008:734–9nconsistent with those we previously obtained in the same
atient cohort showing that a persistent platelet reactivity to
DP is a predictor of DES thrombosis, because in the
revious study, the group of patients with residual platelet
eactivity to ADP includes patients with associated residual
latelet reactivity to arachidonic acid (14).
One-half of the patients with nonresponsiveness to clo-
idogrel have associated nonresponsiveness to aspirin.
gain, among the dual nonresponders, more than one-half
f patients have high residual platelet reactivity by collagen
timulus that explores different pathways other than
yclooxygenase-1 and P2Y12 for the antithrombotic effect
f aspirin and clopidogrel. These associations can be ex-
lained, at least in part, by the fact that the different
athways involved in platelet reactivity can influence each
ther at different degrees. Arachidonic acid–induced platelet
ggregation is mainly influenced by the inhibition of the
hromboxane synthesis, and ADP-induced platelet aggre-
ation is mainly sensitive to the inhibition of P2Y1 and
2Y12 receptors (16–18). However, evidence exists of the
ole of the P2Y12 receptor, the target of clopidogrel, as a
unctional regulator of thromboxane-A2 generation conse-
uent to protein-activated receptor stimulation, whereas
DP-induced and collagen-induced platelet aggregation
re affected to some extent by aspirin (19,20). Collagen acts
n GP VI and directly activates the receptor function of GP
Ib/IIIa to induce a maximal platelet aggregation response
21). Signaling by these receptors causes the secretion of
DP, which also participates in GP IIb/IIIa activation.
We did not use tests related to the specific pathways of
hromboxane generation and ADP signaling in platelets,
nd as a consequence, the underlying mechanisms of aspi-
in, clopidogrel, or dual nonresponsiveness remain unclear.
owever, it seems likely that an abnormal response to 2 or
different platelet aggregation stimuli after a clopidogrel
oading dose of 600 mg could define a primary abnormal
latelet function as a main cause of thrombotic events, and
hat “aggressive blood” makes the patient a “vulnerable
atient.”
Clinically it seems relevant that a single platelet aggrega-
ion assessment after clopidogrel loading may provide a
efinite risk profile for DES thrombosis despite the lack of
tandardization in definition of clopidogrel and aspirin
esistance (22), and the fact that in vitro platelet respon-
Predictors of DES Thrombosisand the Composite of Cardiac Death and DES T
Table 3 Predictors of DES Thrombosisand the Composite of Cardiac Deat
DES T
Hazard Ratio (9
Dual nonresponsiveness 3.18 (1.14–8
Total stent length per 1-mm increase 1.01 (1.00–1
Age per 1-yr increase 1.05 (1.00–1
LVEF per 1% increase 0.94 (0.91–0
CI  confidence interval; DES  drug-eluting stent; LVEF  left ventriiveness may be quite variable because of the influence ofeveral factors, such as inadequate generation of the active
rug metabolite of clopidogrel or differences in the rate of
ntestinal absorption of antiplatelet drugs (18,21,23). Again,
n this study the majority of patients had an acute coronary
yndrome or ST-segment elevation acute myocardial infarc-
ion, which are conditions associated with higher baseline
latelet reactivity compared with stable coronary artery
isease (24,25), and it is surprising that a single platelet
eactivity assessment in the acute phase of coronary artery
isease maintains a high predictive value for subacute or late
ES thrombosis when most patients are stable and the
vidence of the acuity of coronary disease has disappeared.
tudy limitations. The deferred blood sample collection in
atients who received GP IIb/IIIa inhibitors could have the
otential for a confounding effect on the assessment of
esidual platelet reactivity to the collagen stimulus. How-
ver, this confounding effect is unlikely, considering the
elay from the GP IIb/IIIa inhibitor administration and the
ssessment of platelet reactivity.
The analysis according to platelet responsiveness to both
spirin and clopidogrel decreases the statistical power of the
ample size used in the RECLOSE trial, which was
ufficiently powered for the responsiveness to clopidogrel
ith or without nonresponsiveness to aspirin. However, the
oncentration of DES thrombosis and mortality in the dual
onresponders patient group is impressive, whereas no other
ata from prospective studies on dual aspirin and clopi-
ogrel nonresponsiveness in patients treated with DES are
urrently available. This limitation highlights the need for a
arge-scale confirmatory trial; meanwhile, the findings of
his study should be considered as hypothesis generating
ather than offering a definitive answer.
eprint requests and correspondence: Dr. David Antoniucci,
ivision of Cardiology, Careggi Hospital, Viale Pieraccini,
-50134, Florence, Italy. E-mail: david.antoniucci@virgilio.it.
EFERENCES
1. Metha SR, Yusuf S, Peters RJG, et al. Effects of pre-treatment with
clopidogrel and aspirin followed by long-term therapy in patients
undergoing percutaneous coronary intervention: the PCI-CURE
study. Lancet 2001;358:527–33.
2. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual
bosis
DES Thrombosis
osis Cardiac Death and DES Thrombosis
) p Value Hazard Ratio (95% CI) p Value
0.027 2.94 (1.17–7.41) 0.022
0.023 1.01 (1.01–1.02) 0.009
0.050 1.05 (1.01–1.10) 0.023
0.001 0.93 (0.90–0.96) 0.001
ection fraction.hrom
h and
hromb
5% CI
.83)
.02)
.10)
.97)oral antiplatelet therapy following percutaneous coronary intervention:
a randomized controlled trial. JAMA 2002;288:2411–20.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
K
739JACC Vol. 52, No. 9, 2008 Gori et al.
August 26, 2008:734–9 Dual Nonresponsiveness to Clopidogrel and Aspirin3. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of random-
ized and registry comparison of ticlopidine with clopidogrel after
stenting. J Am Coll Cardiol 2002;39:9–14.
4. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in
drug-eluting coronary stents after discontinuation of antiplatelet ther-
apy. Lancet 2004;364:1519–21.
5. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental
cost-effectiveness of drug eluting stents compared with a third gener-
ation bare-metal stents in a real-world setting: randomised Basel Stent
Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921–9.
6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and
outcome of thrombosis after successful implantation of drug-eluting
stents. JAMA 2005;293:2126–30.
7. Park D-W, Park S-W, Park K-H, et al. Frequency and risk factors for
stent thrombosis after drug-eluting stent implantation during long-
term follow-up. Am J Cardiol 2006;98:352–6.
8. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in
patients with acute myocardial infarction. Circulation 2004;109:
3171–5.
9. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet
reactivity in patients with stent thrombosis. J Am Coll Cardiol
2005;46:1827–32.
0. Gurbel PA, Bliden KP, Guyer BS, et al. Platelet reactivity in patients
and recurrent events post-stenting. J Am Coll Cardiol 2005;46:
1820–6.
1. Ajzenberg G, Aubry P, Huisse MG, et al. Enhanced shear-induced
platelet aggregation in patients who experienced stent thrombosis.
J Am Coll Cardiol 2005;45:1653–6.
2. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet
reactivity identified low responders to dual antiplatelet therapy at
increased risk of recurrent cardiovascular events after stenting for acute
coronary syndrome. J Thromb Haemost 2006;4:542–9.
3. Hochholzer W, Trenk D, Bestehorn H-P, et al. Impact of the degree
of peri-interventional platelet inhibition after loading with clopidogrel
on early clinical outcome of elective coronary stent placement. J Am
Coll Cardiol 2006;48:1742–50.
4. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet
reactivity after clopidogrel administration on drug-eluting stent
thrombosis. J Am Coll Cardiol 2007;49,24:2312–7. y5. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A
prospective blinded determination of the natural history of aspirin
resistance among stable patients with cardiovascular disease. J Am Coll
Cardiol 2003;41:961–5.
6. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo
and ex vivo: implications for therapy with platelet inhibitory drugs.
Blood 1987;69:180–6.
7. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of
drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980–7.
8. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and
clopidogrel in atherothrombotic disease. Circulation 2007;115:2196–
207.
9. Shankar H, Garcia A, Prabhakar J, Kunapuli SP. P2Y12 receptor-
mediated potentiation of thrombin-induced thromboxane A2 genera-
tion in platelets occurs through regulation of Erk1/2 activation. J
Thromb Haemost 2006;4:638–47.
0. André P, LaRocca T, Delaney SM, et al. Anticoagulants (thrombin
inhibitors) and aspirin synergize with P2Y12 receptor antagonism in
thrombosis. Circulation 2003;108:2697–703.
1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel
loading dose during coronary stenting: effects on drug response and
interindividual variability. Eur Heart J 2004;5:1903–10.
2. Gurbel PA, Becker RC, Mann KG, Steinubl SR, Michelson AD.
Platelet function monitoring in patients with coronary artery disease.
J Am Coll Cardiol 2007;50:1822–34.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in
individual responsiveness to clopidogrel: clinical implications, manage-
ment, and future perspectives. J Am Coll Cardiol 2007;49:1505–16.
4. Patel PB, Pfau SE, Cleman MW, et al. Comparison of coronary artery
specific leukocyte platelet conjugate formation in unstable versus stable
angina pectoris. Am J Cardiol 2004;93:410–3.
5. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath
N. Platelet function in clopidogrel-treated patients with acute coronary
syndrome. Blood Coagul Fibrinolysis 2007;18:335–9.
ey Words: drug-eluting stent y stent thrombosis y nonresponsiveness
clopidogrel.
